Is MYRIAD GENETICS INC (MYGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 43.6% / 30% | 31.1% / 30% | 23.9% / 30% | 0.22% / 5% | ✗ NOT HALAL |
| DJIM | 43.6% / 33% | 31.1% / 33% | 23.9% / 33% | 0.22% / 5% | ✗ NOT HALAL |
| MSCI | 29.7% / 33% | 21.2% / 33% | 16.3% / 33% | 0.22% / 5% | ✓ HALAL |
| S&P | 43.6% / 33% | 31.1% / 33% | 23.9% / 33% | 0.22% / 5% | ✗ NOT HALAL |
| FTSE | 29.7% / 33% | 21.2% / 33% | 16.3% / 50% | 0.22% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 69.9% | |
| Operating Margin | -1.4% | |
| Net Margin | -44.4% | |
| Return on Equity (ROE) | -68.5% | |
| Return on Assets (ROA) | -4.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $2M |
| Free Cash Flow | -$26M |
| Total Debt | $210M |
| Debt-to-Equity | 57.0 |
| Current Ratio | 2.5 |
| Total Assets | $707M |
Price & Trading
| Last Close | $4.62 |
| 50-Day MA | $5.03 |
| 200-Day MA | $6.10 |
| Avg Volume | 1.6M |
| Beta | 1.9 |
|
52-Week Range
$3.76
| |
About MYRIAD GENETICS INC (MYGN)
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MYRIAD GENETICS INC (MYGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MYRIAD GENETICS INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MYRIAD GENETICS INC's debt ratio?
MYRIAD GENETICS INC's debt ratio is 43.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 29.7%.
What are MYRIAD GENETICS INC's key financial metrics?
MYRIAD GENETICS INC has a market capitalization of $400M, and revenue of $824M. The company maintains a gross margin of 69.9% and a net margin of -44.4%. Return on equity stands at -68.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.